Last reviewed · How we verify
VC005 Tablets
VC005 Tablets is a small molecule drug that targets the SGLT2 receptor.
VC005 Tablets is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | VC005 Tablets |
|---|---|
| Sponsor | Jiangsu vcare pharmaceutical technology co., LTD |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, VC005 Tablets reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo (PHASE2)
- Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. (PHASE3)
- Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis (PHASE3)
- Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. (PHASE2)
- Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis. (PHASE1)
- Multiple-dose Escalation Clinical Study of VC005 Tablets in Healthy Subjects (PHASE1)
- Pharmacokinetics and Pharmacodynamics Clinical Study of VC005 Tablets in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VC005 Tablets CI brief — competitive landscape report
- VC005 Tablets updates RSS · CI watch RSS
- Jiangsu vcare pharmaceutical technology co., LTD portfolio CI